{
  "Figure": "1-s2.0-S1556086415320517-main_page3_47.jpg",
  "Figure_title": "9. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582–1591. 10. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small- cell lung cancer. J Clin Oncol 2010;28:1387–1394. 11. Jackman D, Pao W, Riely GJ, et al. Clinical deﬁnition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357– 360. 12. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontin- uation and reinitiation of erlotinib or geﬁtinib in patients with acquired "
}